‘More people will die from pancreatic cancer’: How COVID-19 ...

More people with pancreatic cancer will die from the disease if the COVID-19 crisis continues to demand the lion’s share of clinical time and resources.

AZ, Merck add pancreatic cancer to Lynparza’s growing use li...

AZ’s Lynparza inches towards ‘game changer’ okay in pancreat...

Halozyme abandons cancer R&D as lead drug failed

Lilly's $1.6bn cancer drug draws blank in pancreatic cancer ...

Eli Lilly is looking at other uses for its new cancer immunotherapy pegilodecakin after it flopped in a phase 3 pancreatic cancer trial.

AZ/Merck & Co wow ASCO with pancreatic cancer data

Finding targeted therapies for pancreatic cancer has long been an issue for pharma, meaning that for decades the only real option has been a course of chemotherapy, with unpleasant side-eff